This trial is studying a drug to treat a rare brain disorder. Subjects will have regular visits for 96 weeks to monitor safety and effectiveness.
- Vanishing White Matter Disease
1 Primary · 1 Secondary · Reporting Duration: Baseline up to Approximately Week 96
1 Treatment Group
1 of 1
8 Total Participants · 1 Treatment Group
Primary Treatment: ABBV-CLS-7262 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are individuals able to enroll in this experimental procedure at present?
"According to records on clinicaltrials.gov, the enrollment period for this study is still ongoing. The trial was initially posted on March 1st 2023 and recently modified six days ago." - Anonymous Online Contributor
What is the extent of participation in this experiment?
"Affirmative. On clinicaltrials.gov, there is evidence that this medical trial is actively seeking to include participants in its research. The trail was opened on March 1st 2023 and recently updated on the 6th of the same month. A total of 8 volunteers are needed between a single site for enrolment into the study." - Anonymous Online Contributor
Has ABBV-CLS-7262 been endorsed by the FDA?
"There is scarce clinical data available that indicates ABBV-CLS-7262's safety and efficacy, thus receiving a score of 1." - Anonymous Online Contributor